Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2014

View Archived Issues

Sinovac files to advance proprietary H7N9 vaccine to clinical trials in China

Aerie begins dosing in phase IIb study of combination product for glaucoma or ocular hypertension

Radiotracer [18F]VM-4-037 evaluated in phase II renal cancer study

Evidence of activity seen with MPX in phase I prostate cancer study

Roche discloses novel mGlu5 receptor positive allosteric modulators

Scripps Florida awarded grant to develop new lung cancer treatments

Boehringer Ingelheim and Duke Clinical Research Institute form partnership for IPF

Miraculins and Alere shift focus of endoglin program

Actelion's Opsumit now available in Germany for PAH

XBiotech and EMA agree on phase III registration study for Xilonix

Vanda's Hetlioz becomes first FDA-approved treatment for non-24-hour sleep-wake disorder

Taxis reports development and preclinical characterization of orally available bactericidal prodrugs

French researchers design new gene sequences for DMD

3D pluripotent stem cell culture system defined

PsychoGenics obtains license to mouse model for the study of neurodegenerative diseases

Alethia Biotherapeutics patents new humanized MAbs for bone disorders

Enanta Pharmaceuticals reports results from four interferon-free studies in HCV infection

Identification of a small-molecule lysyl-tRNA synthetase inhibitor that prevents metastasis

Phase III trial of Eisai's lenvatinib meets primary endpoint in treatment of thyroid cancer

Stelic Institute & Co. divulges novel siRNAs for gastrointestinal disorders

Daiichi Sankyo updates progress of third quarter of fiscal 2013

Genmab prepares new antibodies for cancer and other disorders

Bionomics reports encouraging results from phase I/II trial of BNC-105 in ovarian cancer

European Commission grants orphan drug designation to Hybrigenics' inecalcitol for CLL

Eisai set to launch vascular embolization device DC Bead in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...